Suppression of membrane vesiculation: A possible anticoagulant, antimetastatic and anti-inflammatory effect of heparin

Heparin: Properties, Uses and Side Effects

Volumn , Issue , 2012, Pages 27-57

  Kralj Iglič, Veronika ^a   Šuštar, Vid ^a   Hägerstrand, Henry ^b   Frank, Mojca ^a,c   Janša, Rado ^c  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84871496624     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (159)

1. Baj-Krzyworzeka, M; Szatanek, R; Weglarczyk, K; Baran, J; Urbanowicz, B; Branski, P; Ratajczak, MZ; Zembala, M. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother, 2006 55, 808-818.
2. Ratajczak, J; Miekus, K; Kucia, M; Zhang, J; Reca, R; Dvorak, P; Ratajczak, MZ. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia, 2006 20, 847-856.
3. Fevrier, B; Vilette, D; Archer, F; Loew, D; Faigle, W; Vidal, M; Laude, H; Raposo, G. Cells release prions in association with exosomes. Proc Natl Acad Sci USA, 2004 101, 9683-9688.
4. Robertson, C; Booth, SA; Beniac, DR; Coulthart, MB; Booth, TF; McNicol, A. Cellular prion protein is released on exosomes from activated platelets. Blood, 2006 107, 3907-3911.
5. Vella, LJ; Greenwood, DLV; Cappai, R; Scheerlinck, JP; Hill, AF. Enrichment of prion protein in exosomes derived from ovine cerebral spinal fluid. Vet Immunol Immunop, 2008 124, 385-393.
6. Reich, CF; Pisetsky, DS. The content of DNA and RNA in microparticles released by Jurkat and HL-60 cells undergoing in vitro apoptosis. Exp Cell Res, 2009 315, 760-768.
7. Pelchen-Matthews, A; Raposo, G; Marsh, M. Endosomes, exosomes and Trojan viruses. Trends Microbiol, 2004 12, 310-316.
8. Coltel, N; Combes, V; Wassmer, SC; Chimini, G; Grau, GE. Cell vesiculation and immunopathology: implications in cerebral malaria. Microbes Infect, 2006 8, 2305-2316.
9. Silverman, JM; Reiner, NE. Exosomes and other microvesicles in infection biology: organelles with unanticipated phenotypes. Cell Microbiol, 2011 13, 1-9.
10. Janowska-Wieczorek, A; Marquez-Curtis, LA; Wysoczynski, M; Ratajczak, MZ. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion, 2006 46, 1199-1209.
11. Szajnik, M; Czystowska, M; Szczepanski, MJ; Mandapathil, M; Whiteside, TL. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS ONE, 2010 5: e11469. doi:10.1371/journal.pone.0011469.
12. Ardoin, SP; Shanahan, JC; Pisetsky, DS. The role of microparticles in inflammation and thrombosis. Scandinavian J Immunol, 2007 66, 159-165.
13. Lopez, JA; Del Conde, I; Shrimpton, CN. Receptors, rafts, and microvesicles in thrombosis and inflammation. J Thromb Haemost, 2005 3, 1737-1744.
14. Wolf, P. The nature and significance of platelet products in human plasma. Br J Haematol, 1967 13, 269-288.
15. Rumsby, MG; Trotter, J; Allan, D; Michell, RH. Recovery of membrane micro-vesicles from human erythrocytes stored for transfusion: a mechanism for the erythrocyte discocyte-to-spherocyte shape transformation. Biochem Soc Trans, 1977 5, 126-128.
16. Greenwalt, TJ. The how and why of exocytic vesicles. Transfusion, 2006 46, 143-152.
17. Simak, J; Gelderman, MP. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev, 2006 20, 1-26.
18. Allan, D; Billah, MM; Finean, JB; Michell, RH. Release of diacylglycerol-enriched vesicles from erythrocytes with increased intracellular Ca2+. Nature, 1976 261, 58-60.
19. Araki, T. Release of cholesterol-enriched microvesicles from human erythrocytes caused by hypertonic saline at low-temperatures. FEBS Lett, 1979 97, 237-240.
20. Hägerstrand, H; Isomaa, B. Vesiculation induced by amphiphiles in erythrocytes. Biochim Biophys Acta, 1989 982, 179-186.
21. Hägerstrand, H; Bobrowska-Hägerstrand, M; Lillsunde, I; Isomaa, B. Vesiculation induced by amphiphiles and ionophore A23187 in porcine platelets: a transmission electron microscopic study. Chem-Biol Interact, 1996 101, 115-126.
22. Cerri, C; Chimenti, D; Conti, I; Neri, T; Paggiaro, P; Celi, A. Monocyte/macrophage-derived microparticles up-regulate inflammatory mediator synthesis by human airway epithelial cells. J Immunol, 2006 177, 1975-1980.
23. Martinez, MC; Tesse, A; Zobairi, F; Andriantsitohaina, R. Shed membrane microparticles from circulating and vascular cells in regulating vascular function. Am J Physiol Heart Circ Physiol, 2005 288, 1004-1009.
24. Brogan, PA; Dillon, MJ. Endothelial microparticles and the diagnosis of the vasculitides. Intern Med, 2004 43, 1115-1119.
25. Combes, V; Simon, AC; Grau, GE; Arnoux, D; Camoin, L; Sabatier, F; Mutin, M; Sanmarco, M; Sampol, J; Dignat-George, F. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest, 1999 104, 93-102.
26. Shet, AS; Aras, O; Gupta, K; Hass, MJ; Rausch, DJ; Saba, N; Koopmeiners, L; Key, NS; Hebbelet, RP. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood, 2003 102, 2678-2683.
27. Ullal, AJ; Pisetsky, DS. The release of microparticles by Jurkat leukemia T cells treated with staurosporine and related kinase inhibitors to induce apoptosis. Apoptosis, 2010 15, 586-596.
28. Morel, O; Jesel, L; Freyssinet, JM; Toti, F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol, 2011 31, 15-26.
29. Taylor, DD; Black, PH. Neoplastic and developmental importance of plasma membrane vesicles. Am Zool, 1987 26, 411-415.
30. Black, PH. Shedding from normal and cancer-cell surfaces, New Engl J Med, 1980 303, 1415-1416.
31. Taylor, DD; Chou, IN; Black, PH. Isolation of plasma-membrane fragments from cultured murine melanoma-cells. Biochem Biophys Res Commun, 1983 113, 470-476.
32. Kralj-Iglic, V; Batista, U; Hägerstrand, H; Iglic, A; Majhenc, J; Sok, M. On mechanisms of cell plasma membrane vesiculation. Radiol Oncol, 1998 32, 119-123.
33. Koga, K; Matsumoto, K; Akiyoshi, T; Kubo, M; Yamanaka, N; Tasaki, A; Nakashima, H; Nakamura, M; Kuroki, S; Tanaka, M; Katano, M. Purification, characterization and biological significance of tumor-derived exosomes. Anticancer Res, 2005 25, 3703-3707.
34. Junkar, I; Šuštar, V; Frank, M; Janša, V; Zavec, AB; Rozman, B; Mozetic, M; Hägerstrand, H; Kralj-Iglic, V. Blood and synovial microparticles as revealed by atomic force and scanning electron microscope. Open Autoimmun J, 2009 1, e50-58.
35. Mrvar-Brecko, A; Šsǔtar, V; Janša, V; Štukelj, R; Janša, R; Mujagic, E; Kruljc, P; Iglic, A; Hägerstrand, H; Kralj-Iglic, V. Isolated microvesicles from peripheral blood and body fluids as observed by scanning electron microscope. Blood Cell Mol Dis, 2010 44, 307-312.
36. Berckmans, RJ; Sturk, A; van Tienen, LM; Schaap, MC; Nieuwland, R. Cell-derived vesicles exposing coagulant tissue factor in saliva. Blood, 2011 117, 3172-3180.
37. Gross, PL. Salivary microvesicles clot blood. Blood, 2011 117, 2989.
38. Pascual, M; Steiger, G; Sadallah, S; Paccaud, JP; Carpentier, JL; James, R; Schifferli, JA. Identification of membrane bound CR1 (CD35) in human urine: evidence for its release by glomerular podocytes. J Exp Med, 1994 179, 889-899.
39. del Conde, I; Bharwani, LD; Dietzen, DJ; Pendurthi, U; Thaigarajan, P; Lopez, JA. Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Haemost, 2007 5, 70-74.
40. Müller, I; Klocke, A; Alex, M; Kotzsch, M; Luther, T; Morgenstern, E; Zieseniss, S; Zahler, S; Preissner, K; Engelmann, B. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J, 2003 17, 476-478.
41. Rickles, FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb, 2006 35, 103-110.
42. Rak, J; Milsom, C; May, L; Klement, P; Yu, J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost, 2006 32, 54-70.
43. Dignat-George, F; Camoin-Jau, L; Sabatier, F; Arnoux, D; Anfosso, F; Bardin, N; Veit, V; Combes, V; Gentile, S; Moal, V; Sanmarco, M; Sampol, J. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost, 2004 91, 667-673.
44. Janowska-Wieczorek, A; Wysoczynski, M; Kijowski, J; Marquez-Curtis, L; Machalinski, B; Ratajczak, J; Ratajczak, MZ. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer, 2005, 113, 752-760.
45. Boulanger, CM, Amabile, N, Tedgui, A. Circulating microparticles -A potential prognostic marker for atherosclerotic vascular disease. Hypertension, 2006 48, 180-186.
46. Galli, M; Grassi, A; Barbui, T. Platelet-derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Haemost, 1996 75, 427-431.
47. Jimenez, JJ; Jy, W; Mauro, LM; Hortsman, LL; Ahn YS. Elevated endothelial microparticles in thrombotic trombocitopenic purpura: findings from brain and renal mirovascular cell culture and patients with active disease. Br J Haematol, 2001 112, 81-90.
48. Ståhl, AL; Sartz, L; Karpman, D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood, 2011 19, 117, 5503-5513.
49. Kanazawa, S; Nomura, S; Kuwana, M; Muramatsu, M; Yamaguchi, K; Fukuhara, S. Monocyte-derived microparticles may be a sign of vascular complication in patients with lung cancer. Lung Cancer, 2003 39, 145-149.
50. Dominguez-Malagon, H; del Carmen Valdez-Carrillo, M; Cano-Valdez, M. Dermatofibroma and dermatofibrosarcoma protuberans: A comparative ultrastructural study. Ultrastructural Pathology, 2006 4, 283-291.
51. Abrahams, VM; Straszewski, SL; Kamsteeg, M; Hanczaruk, B; Schwartz, PE; Rutherford, TJ; Mor, G. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res, 2003 63, 5573-5581.
52. Mallat, Z; Benamer, H; Hugel, B; Benessiano, J; Steg, PG; Freyssinet, JM; Tedgui, A. Elevated levels of shed membrane with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndrome. Circulation, 2000 101, 841-843.
53. Bernal-Mizrachi, L; Jy, W; Fierro, C; Macdonough, R; Velazques, HA; Purow, J; Jimenez, JJ; Horstman, LL; Ferreira, A; de Marchena, E; Ahn, YS. Endothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromes. Int J Cardiol, 2004 97, 439-446.
54. Koga, K; Matsumoto, K; Akiyoshi, T; Kubo, M; Yamanaka, N; Tasaki, A; Inakashima, H; Nakamura, M; Kuroki, S; Tanaka, M; Katano, M. Purification, characterization and biological significance of tumor-derived exosomes. Anticancer Res, 2005 25, 3703-3707.
55. Koga, S; Sugiyama, K; Kugiyama, H; Fukushima, K; Watanabe; T. Sakamoto. Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type 2 diabetes mellitus without obstructive coronary artery disease. Eur Heart J, 2006 27, 817-823.
56. Werner, N; Wassmann, S; Ahlers, P; Kosiol, S; Nickenig, G. Circulating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease. Arterioscler Thromb Vasc Biol, 2006 26, 112-116.
57. Cherian, P; Hankey, GJ; Eikelboom, JW; Thom, J; Baker, RI; McQuillan, A; Staton, J; Yi, Q. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke, 2003 34, 2132-2137.
58. Simak, J; Gelderman, MP. Cell membrane microparticles in blood and blood products: Potentially pathogenic agents and diagnostic markers. Transfus Med Rev, 2006 20, 1-26.
59. Ederhy, S; Di, AE; Mallat, Z; Hugel, B; Janower, S; Meuleman, C; Boccara, F; Freyssinet, JM; Tedgui, A; Cohen, A. Levels of circulating procoagulant microparticles in nonvalvular atrial fibrilation. Am J Cardiol, 2007 100, 989-994.
60. Arteaga, RB; Chirinos, JA; Soriano, AO; Jy, W; Horstman, L; Jimenez, JJ; Mendez, A; Ferreira, A; de Marchena, E; Ahn, YS. Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol, 2006 98, 70-74.
61. Agouni, A; Lagrue-Lak-Hal, AH; Ducluzeau, PH; Mostefai, HA; Draunet-Busson, C; Leftheriotis, G; Heymes, C; Martinez, MC; Andriantsitohaina, R. Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol, 2008 173, 1210-1219.
62. Minagar, A; Jy, W; Jimenez, JJ; Sheremata, WA; Mauro, LM; Mao, WW; Horstman, LL; Ahn, YS. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology, 2001 56, 1319-1324.
63. Michelsen, AE; Noto, AT; Brodin, E; Mathiesen, EB; Brosstad, F; Hansen, JB. Elevated levels of platelet microparticles in carotid atherosclerosis and during the postprandial state. Thromb Res, 2009 123, 881-886.
64. Simak, J; Holada, K; Risitano, AM; Zivny, JH; Young, NS; Vostal, JG. Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal hemoglobinuria. Br J Haematol, 2004 125, 804-813.
65. Kozuma, Y; Sawahata, Y; Takei, Y; Chiba, S; Ninomiya, H. Procoagulant properties of microparticles released from red blood cells in paroxysmal nocturnal haemoglobinuria. Br J Haematol, 2011 152, 631-639.
66. Ogura, H; Tanaka, H; Koh, T; Fujita, K; Fujimi, S; Nakamori, Y; Hosotsubo, H; Kuwagata, Y; Shimazu, T; Sugimoto, H. Enhanced production of endothelial microparticles with increased binding to leukocytes in patients with severe systemic inflammatory response syndrome. J Trauma Inj Inf Crit Care, 2004 56, 823-831.
67. Abid Hussein, MN; Meesters, EW; Osmanovic, N; Romijn, FP; Nieuwland, R; Sturk, A. Antigenic characterization of endothelial cell-derived microparticles and their detection ex vivo. J Thromb Haemost, 2003 1, 2434-2443.
68. Sellam, J; Proulle, V; Jüngel, A; Ittah, M; Miceli Richard, C; Gottenberg, JE; Toti, F; Benessiano, J; Gay, S; Freyssinet, JM; Mariette, X. Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther, 2009 11, R156.
69. Flores-Nascimento, MC; Beltrame, MP; De Paula, EV; Montalvao, AL; Pereira, FG, Orsi, FL; Lorand-Metze, I; Annichino-Bizzacchi, JM. Microparticles in deep venous thrombosis, antiphospholipid syndrome and Factor V Leiden. Platelets, 2009 20, 367-375.
70. Diamant, M; Nieuwland, R; Pablo, RF; Sturk, A; Smit, JW; Radder, JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation, 2002 106, 2442-2447.
71. Sabatier, F; Roux, V; Anfosso, F; Camoin, L; Sampol, J; Dignat-George, F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood, 2002 99, 3962-3970.
72. Chirinos, JA; Heresi, GA; Velasquez, H; Jy, W; Jimenez, JJ; Ahn, E; Horstman, LL; Soriano, AO; Zambrano, JP; Ahn, YS. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J of the Amer Coll of Card, 2005 45, 1467-1471.
73. Ay, C; Freyssinet, JM; Sailer, T; Vormittag, R; Pabinger, I. Circulating procoagulant microparticles in patients with venous thromboembolism. Thromb Res, 2009 123, 724-726.
74. Garcia Rodriguez, P; Eikenboom, HCJ; Tesselaar, MET; Huisman, MV; Nijkeuter, M; Osanto, S. Plasma levels of microparticles-associated tissue factor activity in patients with clinically suspected pulmonary embolism. Thromb Res, 2010 126, 345-349.
75. Kim, JW; Wieckowski, E; Taylor, DD; Reichert, TE; Watkins, S; Whiteside, TL. Fas-ligand positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res, 2005 11, 1010-1020.
76. Laude, I; Rongieres, C; Boyer, C; Wolf, M; Mairovitz, V; Hugel, B; Freyssinet, JM; Frydman, R; Meyer, D; Eschwège, V. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost, 2001 85, 18-21.
77. Carp, H; Dardik, R; Lubetsky, A; Salomon, O; Eskaraev, R; Rosenthal, E; Inbal, A. Prevalence of circulating procoagulant microparticles in women with recurrent miscarriage: a case-controlled study. Hum Reprod, 2004 19, 191-195.
78. Joop, K; Nieuwland, R; Berrckmans, RJ; Berkhout, J; Romijn, FP; Hack, CE; Sturk, A. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanism. Thromb Haemost, 2001 85, 810-820.
79. Bretelle, F; Sabatier, F; Desprez, D; Camoin, L; Grunebaum, L; Combes, V; D'Ercole, C; Dignat-George, F. Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intra uterine growth restriction. Thromb Haemost, 2003 89, 486-492.
80. van Beers, EJ; Schaap, MC; Berckmans, RJ; Nieuwland, R; Sturk, A; van Doormaal, FF; Meijers, JC; Biemond, BJ; CURAMA, study group. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica, 2009 94, 1513-1519.
81. Ando, M; Ieata, A; Ozeki, Y; Tsuchiya, K; Akiba, T; Nihei, H; Circulating platelet derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int, 2002 62, 1757-1763.
82. Amabile, N; Guerin, AP; Leroyer, A; Mallat, Z; Nguyen, C; Boddaert, J; London, GM; Tedgui, A; Boulanger, CM. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol, 2005 16, 3381-3388.
83. Preston, RA; Jy, W; Jimenez, JJ; Mauro, LM; Horstman, LL; Valle, M; Aime, G; Ahn, YS. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension. 2003 41, 211-217.
84. Bakouboula, B; Morel, O; Faure, A; Zobairi, F; Jesel, L; Trinh, A; Zupan, M; Canuet, M; Grunebaum, L; Brunette, A; Desprez, D; Chabot, F; Weitzenblum, E; Freyssinet, JM; Chaouat, A; Toti, F. Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. Am J Respir Crit Care Med, 2008 177, 536-543.
85. Ferreira, AC; Peter, AA; Mendez, AJ; Jimenez, JJ; Mauro, LM; Chirinos, JA; Ghany, R; Virani, S; Garcia, S; Horstman, LL; Purow, J; Jy, W; Ahn, YS; de Marchena, E. Postprandial hypertriglyceridemia increases circulating levels of endothelial cell microparticles. Circulation, 2004 110, 3599-3603.
86. Germain, SJ; Sacks, GP; Sooranna, SR; Sargent, IL; Redman, CW. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J Immunol, 2007 178, 5949-5956.
87. Sugimura, M; Kobayashi, T; Shu, F; Kanayama, N; Terao, T. Annexin V inhibits phosphatidylserine-induced intrauterine growth restriction in mice. Placenta, 1999 20, 555-560.
88. Pierangeli, SS; Chen, PP; Gonzalez, EB. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol, 2006 13, 366-375.
89. Trousseau A. Plegmasia alba dolens. Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris. 1865 5, 281-332.
90. Sack, GH; Levin, J; Bell, WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore), 1977 56, 1-37.
91. Kim, YJ; Borsig, L; Han, HL; Varki, NM; Varki, A. Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am J Pathol, 1999 155, 461-472.
92. Varki, NM; Varki, A. Heparin inhibition of selectin mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost., 2002 28, 53-66.
93. Kim, YJ; Borsig, L; Varki, NM; Varki, A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A, 1998 95, 9325-9330.
94. Pineo, GF; Brain, MC; Gallus, AS; Hirsh, J; Hatton, MW; Regoeczi, E. Tumors, mucus production, and hypercoagulability. Ann N Y Acad Sci, 1974 230, 262-270.
95. Borsig, L; Wong, R; Feramisco, J; Nadeau, DR; Varki, NM; Varki, A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A, 2001 98, 3352-3357.
96. Borsig, L; Wong, R; Hynes, RO; Varki, NM; Varki, A. Synergistic effects of L-and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A, 2002 99, 2193-2198.
97. Zacharski, LR; Schned, AR; Sorenson, GD. Occurrence of fibrin and tissue factor antigen in human small cell carcinoma of the lung. Cancer Res, 1983 43, 3963-3968.
98. Rao, LV. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev, 1992 11, 249-266.
99. Callander, NS; Varki, N; Rao, LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer, 1992 70, 1194-1201.
100. Rak, J; Milsom, C; May, L; Klement, P; Yu, J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost, 2006 32, 54-70.
101. Rak, J; Yu, JL; Luyendyk, J; Mackman, N. Oncogenes Trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res, 2006 66, 10643-10646.
102. Varki, A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood, 2007 110, 1723-1729.
103. Polgar, J; Matuskova, J; Wagner, DD. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost, 2005 3, 1590-1596.
104. Angelova, MI; Soleau, S; Meleard, P; Faucon, JP; Bothorel, P. Preparation of giant vesicles by external AC electric fields. Kinetics and applications. Prog Colloid Polym Sci, 1992 89, 127-131.
105. Montes, LR; Alonso, A; Goñi, FM; Bagatolli, LA. Giant unilamellar vesicles electroformed from native membranes and organic lipid mixtures under physiological conditions. Biophys J, 2007 15, 3548-3554.
106. Bagatolli, LA; Parasassi, T; Gratton, E. Giant phospholipid vesicles: comparison among the whole lipid sample characteristics using different preparation methods: A two photon fluorescence microscopy study. Chem Phys Lipids, 2000 105, 135-147.
107. Käs, J; Sackmann, E. Shape transitions and shape stability of giant phospholipid vesicles in pure water induced by area-to-volume changes. Biophys J, 1991 60, 825-844.
108. Lipowsky, R. The conformation of membranes. Nature, 1991 349, 475-481.
109. Kralj-Iglic, V; Babnik, B; Gauger, DR; May, S; Iglic, A. Quadrupolar ordering of phospholipid molecules in narrow necks of phospholipid vesicles. J Stat Phys 2006 125, 727-752.
110. Iglic, A; Kralj-Iglic, V. Effect of anisotropic properties of membrane constituents on stable shape of membrane bilayer structures. In: Tien, HT; Ottova-Leitmannova, A, editors. Planar Lipid Bilayers (BLMs) and their Applications. Amsterdam: Elsevier; 2003; 143-172.
111. Urbanija, J; Tom̌ic, N; Lokar, M; Ambrǒic, A; Cucnik, S; Rozman, B; Kandǔer, M; Iglic, A; Kralj-Iglic, V. Coalescence of phospholipid membranes as a possible origin of anticoagulant effect of serum proteins. Chem Phys Lipids, 2007 150, 49-57.
112. Ambrǒic, A; Cucnik, S; Tom̌ic, N; Urbanija, J; Lokar, M; Babnik, B; Rozman, B; Iglic, A; Kralj-Iglic V. Interaction of giant phospholipid vesicles containing cardiolipin and cholesterol with ß2-glycoprotein-I and anti-ß2-glycoprotein-I antibodies. Autoimmun Rev, 2006 6, 10-15.
113. Frank, M; Mancek-Keber, M; Křan, M; Sodin-̌emrl, S; Jerala, R; Iglic, A; Rozman, B; Kralj-Iglic, V. Prevention of microvesiculation by adhesion of buds to the mother cell membrane -a possible anticoagulant effect of plasma. Autoimmun Rev, 2008 7, 240-245.
114. Urbanija, J; Bohinc, K; Bellen, A; Maset, S; Iglic, A; Kralj-Iglic, V; Kumar, P.B.S. Attraction between negatively charged surfaces mediated by spherical counterions with quadrupolar charge distribution. J Chem Phys, 2008 129, 105101.
115. May, S; Iglic, A; Rěcic, J; Maset, S; Bohinc, K. Bridging like-charged macroions through long divalent rodlike ions. J Phys Chem B, 2008 112, 1685-1692.
116. Bohinc, K; Zelko, J; Kumar, PB; Iglic, A; Kralj-Iglic, V. Attraction of like-charged surfaces mediated by spheroidal nanoparticles with spatially distributed electric charge: Theory and simulation. Leitmannova, A; Liu, A, editors. Advances in Planar Lipid Bilayers and Liposomes. Amsterdam: Elsevier; 2009; 279-301.
117. Šuštar, V; Janša, R; Frank, M; Hagerstrand, H; Kržan, M; Iglic, A; Kralj-Iglič, V. Suppression of membrane microvesiculation-A possible anticoagulant and anti-tumor progression effect of heparin. Blood Cells Mod Dis, 2009 42, 223-227.
118. McGarry, LJ; Thompson, D. Retrospective database analysis of the prevention of venous thromboembolism with low-molecular-weight heparin in acutely ill medical inpatients in community practice. Clin Ther, 2004 26, 419-430.
119. Hejna, M; Raderer, M; Zielinski, CC. Inhibition of metastases by anticoagulants. J Nat Cancer Inst, 1999 91, 22-36.
120. Smorenburg, SM; Hettiarachchi, RJ; Vink, R; Buller, HR. The effects of unfractionated heparin on survival in patients with malignancy-a systematic review. Thromb Haemost 1999 82, 1600-1604.
121. Zacharski, RL; Ornstein, DL; Mamourian, AC. Low-molecular -weight heparin and cancer. Semin Thromb Hemost, 2000 26, 69-77.
122. Stevenson, JL; Choi, SH; Wahrenbrock, M; Varki, A; Varki, NM. Heparin effects in metastasis and Trouseeau syndrome: anticoagulation is not the primary mechanism. Haem Rep, 2005 1, 59-60.
123. Varki, A; Varki, NM. P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications. Braz J Med Biol Res, 2001 34, 711-717.
124. Deburdeau, P; Elalamy, I; Raignac, A; Meria, P; Gomet, J; Amah, Y; Kort, W; Marty, M; Farge, D; Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer? Supp Care Cancer, 2008 16, 1333-1341.
125. Ornstein, DL; Zacharski, LR. The use of heparin for treating human malignancies. Haemostasis, 1999 29, 48-60.
126. Borsig, L. Selectins facilitate carcinoma metastasis and heparin can prevent them. News Physiol Sci, 2003 19, 16-21.
127. Cliffton, EE; Agostino, D. Effect of inhibitors of fibrinolytic enzymes on development of pulmonary metastases. J Natl Cancer Inst, 1964 33, 753-763.
128. O'Meara, RAO; Jackson, RD. Cytological observations on carcinoma. Irish J Med Sci, 1958 391, 327-328.
129. Berry, D; Lynn, DM; Sasisekharan, R; Langer, R. Poly(beta-amino ester)s promote cellular uptake of heparin and cancer cell death. Chem Biol, 2004 11, 487-498.
130. Chen, X; Xiao, W; Qu, X; Zhou, S. The effect of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro. Cancer Inv, 2008 26, 718-724.
131. Young, E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008 122, 743-752.
132. Ahmed, T; Garrigo, J; Danta, I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med, 1993 329, 90-95.
133. Garrigo, J; Danta, I; Ahmed, T. Time course of the protective effect of inhaled heparin on exercise-induced asthma. Am J Respir Crit Care Med, 1996 153, 1702-1707.
134. Ahmed, T; Gonzalez, BJ; Danta I. Prevention of exercise induced bronchoconstriction by inhaled low-molecular weight heparin. Am J Respir Crit Care Med, 1999 160, 576-581.
135. Bowler, SD; Smith, SM; Laverombe, PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic patients. Am Rev Respir Dis, 1993 147, 160-163.
136. Diamant, Z; Timmers, MC; van der Veen, H; Page, CP; van der Meer, FJ; Sterk, PJ. Effect of inhaled heparin on allergeninduced early and late responses in patients with atopic asthma. Am J Respir Crit Care Med, 1996 153, 1790-1795.
137. Ceyhan, B; Celikel, T. Effect of inhaled heparin on methacholine-induced bronchial hyperactivity. Chest, 1995 107, 1009-1012.
138. Kalpaklioglu, AF; Demirel, YS; Saryal, S; Misirligil, Z. Effect of pretreatment with heparin on pulmonary and cutaneous response. J Asthma, 1997 34, 337-343.
139. Bendstrup, KE; Jensen, JI. Inhaled heparin is effective in exacerbations of asthma. Respir Med, 2000, 94, 174-175.
140. Gaffney, PR; Doyle, CT; Gaffney, A; Hogan, J; Hayes, DP; Annis, P. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol, 1995 90, 220-223.
141. Evans, RC; Wong, VS; Morris, AI; Rhodes, JM. Treatment of corticosteroid-resistant ulcerative colitis with heparin - a report of 16 cases. Ailment Pharmacol Ther 1997 11, 1037-1040.
142. Folwaczny, C; Wiebecke, B; Loeschke, K. Unfractionated heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol, 1999 94, 1551-1555.
143. Saliba MJ. Heparin in the treatment of burns: a review. Burns, 2001 27, 349-358.
144. Conrad HE. Heparin-binding proteins. New York-London: Academic Press; 1998.
145. Nissen, NN; Shankar, R; Gamelli, RL; Singh, A; DiPietro, LA. Heparin and heparin sulphate protect basic fibroblast growth factor from non-enzymic glycosylation. Biochem J 1999 338, 637-642.
146. Weiler, JM; Edens, RE; Lindhardt, RJ; Kapelanski, DP. Heparin and modified heparin inhibit complement activation in vivo. J Immunol, 1992 148, 3210-3215.
147. Elsayed, E; Becker, RC. The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis, 2003 15, 11-18.
148. Guerin, J; Sheng, Y; Reddel, S; Iverson, GM; Chapman, MG; Krilis, SA; Heparin inhibits the binding of ß2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome. J Biol Chem, 2002 277, 2644-2649.
149. Wagenknecht, DR; McIntyre; JA. Interaction of heparin with ß2-glycoprotein I and antiphospholipid antibodies in vitro. Thromb Res, 1992 68, 495-500.
150. Franklin, RD; Kutteh WH. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol, 2003 101, 455-462.
151. Ermel, LD; Marshburn, PB; Kutteh, WH. Interaction of heparin with antiphospholipid antibody (APA) from the sera of women with reccurent pregnancy loss (RPL). Am J Reprod Immunol, 1995 33, 14-20.
152. Masamoto, H; Toma, T; Sakumoto, K; Kanazawa, K. Clearance of antiphospholipid antibodies in pregnancies treated with heparin. Obstet Gynecol, 2001 97, 394-398.
153. Di Simone, N; Meroni PL; D'Asta, M; Di Nicuolo, F; D'Alessio, MC; Caruso, A; Pathogenic role of anti-ß2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. Hum Reprod Update, 2007 13, 189-196.
154. Frank, M; Sodin-̌emrl, S; Rozman, B; Potocnik, M; Kralj-Iglic, V. Effects of low molecular weight heparin on adhesion and vesiculation of phospholipid membranes. A possible mechanism for the treatment of hypercoagulability in antiphospholipid syndrome, Ann NY Acad Sci, 2009 1173, 874-886.
155. Capila, I; Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl, 2002 41, 390-412.
156. Giles, IP; Haley, JD; Nagl S; Isenberg, DA; Latchman, DS; Rahman, A. A systematic analysis of sequences of human antiphospholipid and anti-ß2-glycoprotein I antibodies: the importance of somatic mutations and certain sequence motifs. Semin Arthritis Rheum, 2003 32, 246-265.
157. Giles, I; Lambrianides, N; Pattni, N; Faulkes, D; Latchman, D; Chen, PJ; Pierangeli, S; Isenberg, D; Rahman, A. Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. J. Immunol, 2006 177, 1729-1736.
158. Vannucchi, S; Ruggierro, M; Chiarugi, V. Complexing of heparin with phosphatidylcholine. A possible supramolecular assembly of plasma heparin. Biochem. J. 1985 227, 57-65.
159. de Laat, B; Derksen, RH; Urbanus, RT; de Groot, PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of ß2-glycoprotein I cause LAC and their presence correlates strongly with thrombosis. Blood, 2005 105, 1540-1545.